Many combination therapies, which are often used in the treatment of diseases such as cancer, have failed to secure National Health Service reimbursement in the UK in recent years. This is because the sponsors of different medicines have been reluctant to work together on making the combination therapies cost effective for fear of breaching competition law, the UK’s competition watchdog has said.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?